Overview

Placebo-Corrected Effects of Therapeutic Dose (100 mg) and Supratherapeutic Dose (300 mg) of ITF2357 (Givinostat) and Moxifloxacin on QT/QTC Interval

Status:
Completed
Trial end date:
2021-06-18
Target enrollment:
Participant gender:
Summary
The study will evaluate the effect of a therapeutic dose and a supratherapeutic dose of ITF2357 on the QT/QTc interval.
Phase:
Phase 1
Details
Lead Sponsor:
Italfarmaco
Treatments:
Givinostat hydrochloride
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination